
### [NCIT:C7195](http://purl.obolibrary.org/obo/NCIT_C7195)
**Label:** Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder

**Subclasses:** [NCIT:C27365](http://purl.obolibrary.org/obo/NCIT_C27365) (Adult Primary Cutaneous Anaplastic Large Cell Lymphoma), [NCIT:C6860](http://purl.obolibrary.org/obo/NCIT_C6860) (Primary Cutaneous Anaplastic Large Cell Lymphoma), [NCIT:C7211](http://purl.obolibrary.org/obo/NCIT_C7211) (Childhood Primary Cutaneous Anaplastic Large Cell Lymphoma), [NCIT:C7197](http://purl.obolibrary.org/obo/NCIT_C7197) (Type A Lymphomatoid Papulosis), [NCIT:C7196](http://purl.obolibrary.org/obo/NCIT_C7196) (Borderline Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder), [NCIT:C7199](http://purl.obolibrary.org/obo/NCIT_C7199) (Type C Lymphomatoid Papulosis), 

**Class expressions from DL-Learner:**

- Thing 53.92%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40108](http://purl.obolibrary.org/obo/NCIT_C40108) (Borderline Fallopian Tube Mucinous Tumor))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40107](http://purl.obolibrary.org/obo/NCIT_C40107) (Borderline Fallopian Tube Serous Tumor/Atypical Proliferative Serous Tumor))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40104](http://purl.obolibrary.org/obo/NCIT_C40104) (Fallopian Tube Transitional Cell Carcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40103](http://purl.obolibrary.org/obo/NCIT_C40103) (Fallopian Tube Mucinous Adenocarcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40093](http://purl.obolibrary.org/obo/NCIT_C40093) (Ovarian Squamous Cell Carcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40090](http://purl.obolibrary.org/obo/NCIT_C40090) (Ovarian Seromucinous Carcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40086](http://purl.obolibrary.org/obo/NCIT_C40086) (Ovarian Clear Cell Cystadenofibroma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40083](http://purl.obolibrary.org/obo/NCIT_C40083) (Borderline Ovarian Clear Cell Cystadenofibroma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40082](http://purl.obolibrary.org/obo/NCIT_C40082) (Borderline Ovarian Clear Cell Adenofibroma with Intraepithelial Carcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C4008](http://purl.obolibrary.org/obo/NCIT_C4008) (Recurrent Gallbladder Carcinoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40079](http://purl.obolibrary.org/obo/NCIT_C40079) (Ovarian Clear Cell Adenocarcinofibroma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40075](http://purl.obolibrary.org/obo/NCIT_C40075) (Ovarian Endometrioid Cystadenoma))) 37.44%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C40066](http://purl.obolibrary.org/obo/NCIT_C40066) (Undifferentiated Ovarian Sarcoma))) 37.44%


